Johnson and Johnson released encouraging phase 1b data for their dual-targeting CD19/CD20 CAR-T therapy in relapsed or refractory large B-cell lymphoma patients. The objective response rate was 100% in patients with a single prior therapy and 92% in those with multiple prior treatments. Safety profiles showed manageable adverse events with low incidence of high-grade cytokine release syndrome or neurotoxicity. Presented at the European Hematology Association conference, this therapy aims to improve durability and efficacy over single-antigen CAR-T options.